{"name":"Ospedale San Raffaele","slug":"ospedale-san-raffaele","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Peri","genericName":"Peri","slug":"peri","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Autologous Conditioned Serum","genericName":"Autologous Conditioned Serum","slug":"autologous-conditioned-serum","indication":"Osteoarthritis","status":"phase_2"}]}],"pipeline":[{"name":"Peri","genericName":"Peri","slug":"peri","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Autologous Conditioned Serum","genericName":"Autologous Conditioned Serum","slug":"autologous-conditioned-serum","phase":"phase_2","mechanism":"Autologous Conditioned Serum is a treatment that uses a patient's own blood to stimulate healing and reduce inflammation.","indications":["Osteoarthritis","Rheumatoid Arthritis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOQkMwT1VXTkEtOEgwQWVUMW42WkxjT291S0dXdDVCQ21PcG5sYm9STUhmODdSRi1YckJ0QzdzSWM3Q3NrUVFZMEhnM0RFNUpuOHFwT3NQV2RJMzA0S1dDcnpqOU4zR2JtMzRHa0RxRDlaQ0xfQVY3NldTUl9JeXBZbFdEYUJHRFRjcWZSMktQemplaHNGemt6dTk4ZDRaQkZRVzlSdDgxRmM0RmltY2JPQk80MEItSnV5VWtNUi1HM0x2czVNUDBwREw2emtqOVlQVjZvejA1Qkk3UTVPODljX2NCTmlpZDNqeFlyQnZkTlA3bG1RajZR?oc=5","date":"2026-02-12","type":"pipeline","source":"businesswire.com","summary":"Thetis Pharmaceuticals Expands Scientific Advisory Board with Leading Experts in Inflammatory Bowel Disease - businesswire.com","headline":"Thetis Pharmaceuticals Expands Scientific Advisory Board with Leading Experts in Inflammatory Bowel Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOVGpaU0NMeFA5ci1tMFZLYWFrT1JwdHp5VmgyQld5SDl5UExyZXBROFlnTVliM3hBcmhNT1NUdC16XzFyUTBsdVNYbURJWUFSdmh5SlgxUV9OYzl3eWFxVDJIOV9BclA3dC1ZZkdDajBSQlY1bllXNTFUTWdSRm1TeHRTN0dBZUpwbE9xU0VFYkNsVHF2cV90ckExbm5kN1E0dTMzZnUxRjVLUTZUNTlRdXdNMmxoOVNzaUxHT3o1OC0?oc=5","date":"2026-01-21","type":"pipeline","source":"Il Sole 24 ORE","summary":"A drug originally developed for sleep disorders re-emerges as a candidate against multiple sclerosis - Il Sole 24 ORE","headline":"A drug originally developed for sleep disorders re-emerges as a candidate against multiple sclerosis - Il Sole 24 ORE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNeEJlNms4UnJKZHk2cDhsaTNlMWN0R2VOMXZQSjM5UWFYVzl6aDJuT3NpQlYzR0RSNWlVamNyaGhUSVBVR1d4bEdpdzh0cTRzVUpoVnduWE5TNlJDdkJPa0R4RlRlQU4xS0RTWVN6WlM1Y3BZUi1BWFRJZnFuV1dUX3ZVajhLb043ZTdwMVdWWl9BOVcwUjZtMnhKRUJrMHU1NDJvMg?oc=5","date":"2026-01-16","type":"pipeline","source":"The Pharma Letter","summary":"EC authorization for Waskyra for Wiskott-Aldrich syndrome - The Pharma Letter","headline":"EC authorization for Waskyra for Wiskott-Aldrich syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxPTEJjaS1hdDZBdHl6ZzNoTFZpRl96VlNraWJHcUJrZjFEbnUyTzN1bWFKY091TjVVQXlZM0JMcmtaRXhvdXVsSWxQQUllbG5fckdWN2NCX0Q3S0liOVZyb242M3c5eHpzQUQ3cW9KWDBUQlhmbjRIQ25ueWVZS0xQbzZ2cEhCc0NuVHczOUFpOW4wakthUWhCcjRMX3dyektMV1IwQWFxVTVpNUkyUnFDdjd3X01icGN0WkY3c19FU2RYc09ncjlrMXRPNUZXZ1d1bkRwV0ZsbjdaUmdpZDBycEpNZmgxOURjaVMyRDN2SkZaZDRoRExLcnRfZ1c2dnA5YkJtVDNHcnJYUC1paEk3WkVjbTczNU1DcDhhdmNFTkN2ZlNFVHZmSU52VEFFMkEtWWtPLWEwaXdFWDRmZmFDeEVlem9BczA?oc=5","date":"2025-12-10","type":"regulatory","source":"Ricerca Malattie Genetiche Rare","summary":"Announced FDA approval of a Gene Therapy for Wiskott-Aldrich Syndrome - Ricerca Malattie Genetiche Rare","headline":"Announced FDA approval of a Gene Therapy for Wiskott-Aldrich Syndrome","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE9ZWnF1Q0pBRlhUbjdhdnFFRDFFbHlWeTRTVzhPYzR1cV91S01jdE1Ka21mQnBkZXVqcDBRbHZFdFliYUg1c2M4bUxaN1A5dEZyV1pLc0lMaDA1TjJuODE1RE53?oc=5","date":"2025-08-07","type":"pipeline","source":"ACS Publications","summary":"Polydopamine Nanoparticles as a Potential Non-Pharmaceutical Antioxidant Tool against Mitochondrial Disorders - ACS Publications","headline":"Polydopamine Nanoparticles as a Potential Non-Pharmaceutical Antioxidant Tool against Mitochondrial Disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOalJMd3BMMlo3Yk84azhUV0NKZDF2UlBud2JnVDNSNHk2LWw5TU0xQnpROUJQUnlIQlg3NTBUZHVpRmVKNGdGdzNPY08yRnJTeHh5bHdHZ0dmYWhmcEtLOVNQdEhwZ2QzV2hsRkZZeC1RclFKXzQwZkxWS1B6RnctVjJQX25leExPTl9UNDJ3MnBMbmdyUnhCUmVyamJFTjRHTVJpQQ?oc=5","date":"2025-03-03","type":"regulatory","source":"PharmTech.com","summary":"EMA Gives Positive Opinion to Lilly Treatment for Chronic Lymphocytic Leukemia - PharmTech.com","headline":"EMA Gives Positive Opinion to Lilly Treatment for Chronic Lymphocytic Leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNN1lhRXNCNnRqeF9yLUJTT2t4aUtSMmZxRVVhNjZqaTFrVGVBZzJlRmdMV195ME1Eb0VyNG03a3kwYU10MldIVVFCeWpIS1FpVXRQeXhEeFFhQ0NFZnBOM2JfeFAwSC1NeGxETmlyMmhKLXdmZGdHMUYzX1o3ZVl2dmZBdUYzVkJfOGZUUXdSc2ZNbkxfWEVKRjVLcTdZUWdUdzdVVVV2VGpybXhBMk4xR3dlUFNOTjlpQ1NXM1UxTF93X2R6aWZ2Nw?oc=5","date":"2022-02-09","type":"pipeline","source":"Fierce Biotech","summary":"Engineered TCR-T cells by Fred Hutch, San Raffaele-Intellia fend off evasive leukemia, solid tumors - Fierce Biotech","headline":"Engineered TCR-T cells by Fred Hutch, San Raffaele-Intellia fend off evasive leukemia, solid tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQeUNOMlBkUnFuTFVpeTF5a0d6bDBiaDBtTkRWTDU2SFczSjVSekU0ZlhBb1Q3X1Q4YlFvVFFsVV9mTm8wZkxJY3R1bi1ZVnRLNFY2bVlzUVBCbVR3b3AtMFM1QTIwYmdiVUJnTDJoR3lLZFJiNk9EaHZFOFhYaDJtcHNCSldud1h2clR4ZE1lUmZWUVJKVzUxcG50bw?oc=5","date":"2021-07-09","type":"pipeline","source":"pharmaphorum","summary":"NICE rejects Orchard's gene therapy for rare childhood disease MLD - pharmaphorum","headline":"NICE rejects Orchard's gene therapy for rare childhood disease MLD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9ERWpWcGR3ZGtlMlM4RmtVTTJaTmVJcGdPMjNTUlRtZXdPdm1tNEJiVjItTjZQNi1WM3pndjV2b2NxYUlnemRZUW5WTDJVQkVBRFR2ZkIyZVVMM1ZLTmc?oc=5","date":"2020-04-23","type":"pipeline","source":"nature.com","summary":"Complement as a target in COVID-19? - nature.com","headline":"Complement as a target in COVID-19?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNRkpzSEtsWmRWV0xqdExFWlJpTFl3N0xIU2xLTDV0N2JpakZZdkREMGlTVFZFa0NxaG5oZ0NCXzR0WlZuNDNJYXRUa1kzYjJFTWVFUjBfZy1KN1Ftcmo3anhvWlpXb0l1UjhubFZJWUdvbER2YzRkbkV1enNERFY4ZWVTelVBRFZCb09BXzdqYUw5R2tDU2VBN2lkQnFoWklHM1dEcXFzbFNfNFVyQTRwcURaWmtROFRNY1A5dg?oc=5","date":"2019-04-29","type":"trial","source":"Intellia Therapeutics - investor relations","summary":"Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy - Intellia Therapeutics - investor relations","headline":"Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNOTl6U1BFbTFVYlF2ZGU5dmZtWmJ4dkhuRncwMFlFU3VGZTBVNDJrYlYwVTlVczlEUkVjWUl2aW1zOTJwWlExbGI4NEZTdFR4WTBod3N0Sk12ZUdDaEdiQUxwanlSWUhMUFhxRFRRTE16TlNGWUg1N1NuNFRDR2t4NVdkNEltbHQ0NmdjMDM3dS12SmhaQWtLLQ?oc=5","date":"2015-05-12","type":"pipeline","source":"Clinical Leader","summary":"Keeping Tabs On Gene Therapy? Big Pharma Is Closing In - Clinical Leader","headline":"Keeping Tabs On Gene Therapy? Big Pharma Is Closing In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQOC1DTDZQY0dZd2tMWWlFMU5pVGFyLWIwbHIwVWFHMlVLR2hqNjVYblg1OGtTamZhRlFkdENEQkVMMmhnc3pIQ1RKU3VQeHdBODE4b1BudDh0cmk0SjlReWIxUkp3VERWM2xMRWs2V2tpdXNZSzRRZVdlNjQ2Y09YSVEwSWs5emM5VnNsUnFuZlRsb1FqdkRzQmE5NkdCTlB5eVRGRlZOSFhJQ1NHMFpQSjl5bnFQQjh4NW5BQ01vbDlwMGJLVVJQYmVfcjNPVDJYYjJWeEIxTUR0R0Q1ZnFXTVItTENJWDdRT2QxZFQ4RFlKcmRmMXZEQnd6QjYtNHlxeXdwb1FQTzFBV00?oc=5","date":"2015-05-05","type":"regulatory","source":"GSK","summary":"GSK, Fondazione Telethon and Ospedale San Raffaele announce EU regulatory submission for gene therapy to treat rare disease ADA-SCID - GSK","headline":"GSK, Fondazione Telethon and Ospedale San Raffaele announce EU regulatory submission for gene therapy to treat rare dise","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}